Wednesday, September 28, 2016

Persantin Retard 200mg





Persantin Retard 200 mg



Modified Release Capsules, Hard



dipyridamole






Read all of this leaflet carefully before you start taking this medicine.



  • Keep this leaflet. You may need to read it again.


  • If you have any further questions, ask your doctor or pharmacist.


  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.


  • If any of the side effects gets troublesome or serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.




In this leaflet:



  • 1. What PERSANTIN Retard is and what it is used for


  • 2. Before you take PERSANTIN Retard


  • 3. How to take PERSANTIN Retard


  • 4. Possible side effects


  • 5. How to store PERSANTIN Retard


  • 6. Further information





What Persantin Retard Is And What It Is Used For



The name of your medicine is PERSANTIN Retard. It contains a medicine called Dipyridamole. This belongs to a group of medicines called ‘anti-thrombotic agents’, which are used to help stop blood clots forming.




PERSANTIN Retard is used:



  • To help stop blood clots which may occur if you have had your heart valves replaced.


  • In people who have had a stroke caused by a blood clot in the brain. This medicine reduces the risk of having another stroke.





Before You Take Persantin Retard




Do not take PERSANTIN Retard if you are allergic (hypersensitive) to:



  • Dipyridamole


  • Any of the other ingredients of PERSANTIN Retard (see section 6: Further Information)




Take special care with PERSANTIN Retard



Check with your doctor or pharmacist before taking your medicine if:



  • You have angina or other heart problems (including heart valve or circulation problems) or have had a recent heart attack


  • You have myasthenia gravis (a rare muscle problem)


  • You have any bleeding problems


  • You are pregnant or planning to become pregnant or are breast-feeding

If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking PERSANTIN Retard.





Taking other medicines



Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This includes herbal medicines. This is because PERSANTIN Retard can affect the way some other medicines work. Also some other medicines can affect the way PERSANTIN Retard works.



In particular, tell your doctor or pharmacist if you are taking any of the following medicines:



  • Medicines for high blood pressure


  • Medicines for muscle weakness such as something called a ‘cholinesterase inhibitor’


  • Aspirin (or planning to take aspirin for any condition)


  • Adenosine injection - used for heart problems or tests on the heart


  • Warfarin or other medicines to stop blood clots forming. If so, tell them at your next visit to the anticoagulant clinic that you are now taking PERSANTIN Retard




If you are having heart tests



PERSANTIN Retard contains dipyridamole.

Dipyridamole is also sometimes given as an injection during tests to see if the heart is working properly (also called ‘myocardial imaging’). This means that the test and your medicine may contain the same substance. If you are going to have an injection of dipyridamole, tell the doctor that you are taking PERSANTIN Retard.





Pregnancy and breast-feeding



  • Tell your doctor if you are pregnant or planning to get pregnant.


  • Tell your doctor if you are breast-feeding as PERSANTIN Retard should only be used during breast-feeding if your doctor considers it essential.





How To Take Persantin Retard



Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.




The usual dose is:



  • One capsule twice a day


  • Usually one in the morning and one in the evening


  • It is best to take it with food


  • Swallow the capsule whole


  • Do not crush or chew it



Do not give to children.




If you take more PERSANTIN Retard than you should



If you take more of this medicine than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you, even if there are no capsules left.





If you forget to take PERSANTIN Retard



  • If you forget a dose, take it as soon as you remember it


  • However, if it is time for the next dose, skip the missed dose


  • Do not take a double dose to make up for the forgotten dose



If you have any further questions on the use of this product, ask your doctor or pharmacist.





Possible Side Effects



Like all medicines PERSANTIN Retard can cause side effects, although not everybody gets them.




Allergic reactions



If you have an allergic reaction, stop taking your medicine and see a doctor straight away. The signs may include feeling breathless, runny nose, severe rash with itching, swelling and swelling around the eyes.





Other side effects are:



  • Hot flushes


  • Lowering of blood pressure or increased heart rate


  • Worsening of the symptoms of heart disease such as chest pain and heart beat problems


  • A blood problem called ‘thrombocytopenia’ which can cause bruising and prolonged bleeding from wounds, including during or after surgery



In people who have gallstones, the dipyridamole in this medicine can be absorbed into the gallstones.




The side effects listed below usually go away as treatment continues:



  • Headache or feeling dizzy


  • Being sick (vomiting), feeling sick (nausea), indigestion or diarrhoea


  • Muscle pain



If any of the side effects gets troublesome or serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.





How To Store Persantin Retard



Keep out of the sight and reach of children.



The capsules should not be stored above 25°C.



Do not use PERSANTIN Retard after the expiry date which is stated on the carton and container label after EXP. The expiry date refers to the last day of that month.



Do not open the container until you are ready to start taking the capsules. If you have any capsules left after six weeks, these should not be taken.



Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.





Further Information




What PERSANTIN Retard contains



The active substance is dipyridamole. Each modified release capsule contains dipyridamole 200 mg. PERSANTIN Retard is a modified release capsule which releases the active substance slowly in your body over a number of hours.



The other ingredients in PERSANTIN Retard are: hypromellose, tartaric acid, acacia, povidone, methacrylic acid-methylmethacrylate copolymer (1:2), hypromellose phthalate, Dimethicone 350, triacetin, talc and stearic acid.



The capsule shells contain gelatin, titanium dioxide (E171), red iron oxide (E172) and yellow iron oxide (E172).





What PERSANTIN Retard looks like and contents of the pack



PERSANTIN Retard capsules are red and orange.



PERSANTIN Retard is available in packs of 60 capsules.





Marketing Authorisation Holder and Manufacturer



The Marketing Authorisations for PERSANTIN Retard are held by:




Boehringer Ingelheim Limited

Ellesfield Avenue

Bracknell

Berkshire

RG12 8YS

England



and the capsules are manufactured by:




Boehringer Ingelheim Pharma GmbH & Co. KG

Birkendorfer Strasse 65

88397 Biberach an der Riss

Germany





This leaflet was revised in September 2008.



© Boehringer Ingelheim Limited 2008



43626-07






Prostap SR DCS





1. Name Of The Medicinal Product



PROSTAP® SR DCS 3.75 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Syringe


2. Qualitative And Quantitative Composition



PROSTAP SR Powder: contains 3.75 mg leuprorelin acetate (equivalent to 3.57 mg base).



Sterile Solvent: Each ml contains carmellose sodium 5 mg, mannitol (E421) 50 mg, polysorbate 80 1 mg, glacial acetic acid up to 0.05 mg in Water for Injections.



When reconstituted with Sterile Solvent, the suspension contains 3.75 mg/ml leuprorelin acetate.



For full list of excipients, see section 6.1



3. Pharmaceutical Form



Powder and solvent for suspension for injection in pre-filled syringe



Powder: A sterile, lyophilised, white, odourless powder.



Solvent: A clear, odourless, slightly viscous, sterile solvent.



4. Clinical Particulars



4.1 Therapeutic Indications



(i) Metastatic prostate cancer.



(ii) Locally advanced prostate cancer, as an alternative to surgical castration.



(iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.



(iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.



(v) Management of endometriosis, including pain relief and reduction of endometriotic lesions.



(vi) Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection.



(vii) Preoperative management of uterine fibroids to reduce their size and associated bleeding.



(See Section 5.1)



4.2 Posology And Method Of Administration



Prostate Cancer: The usual recommended dose is 3.75 mg presented as a one month depot injection and administered as a single subcutaneous or intramuscular injection every month. The majority of patients will respond to a 3.75 mg dose. PROSTAP SR therapy should not be discontinued when remission or improvement occurs. As with other drugs administered chronically by injection, the injection site should be varied periodically.



Response to PROSTAP SR therapy may be monitored by clinical parameters and by measuring serum levels of testosterone and acid phosphatase. Clinical studies with leuprorelin acetate have shown that testosterone levels increased during the first 4 days of treatment in the majority of non-orchidectomised patients. They then decreased and reached castrate levels by 2-4 weeks. Once attained, castrate levels were maintained as long as drug therapy continued. If a patient's response appears to be sub-optimal, then it would be advisable to confirm that serum testosterone levels have reached or are remaining at castrate levels. Transient increases in acid phosphatase levels sometimes occur early in the treatment period but usually return to normal or near normal values by the 4th week of treatment.



Endometriosis: The recommended dose is 3.75 mg administered as a single subcutaneous or intramuscular injection every month for a period of 6 months only. Treatment should be initiated during the first 5 days of the menstrual cycle.



In women receiving GnRH analogues for the treatment of endometriosis, the addition of hormone replacement therapy (HRT - an estrogen and progestogen) has been shown to reduce bone mineral density loss and vasomotor symptoms. Therefore if appropriate, HRT should be co-administered with PROSTAP SR taking into account the risks and benefits of each treatment.



Endometrial preparation prior to intrauterine surgery: A single 3.75 mg subcutaneous or intramuscular injection 5-6 weeks prior to surgery. Therapy should be initiated during days 3 to 5 of the menstrual cycle.



Preoperative management of uterine fibroids: The recommended dose is 3.75 mg administered as a single subcutaneous or intramuscular injection every month, usually for 3-4 months but for a maximum of six months.



Elderly: As for adults.



Children: PROSTAP SR is not recommended in children under 18 years due to insufficient data on safety and efficacy in this patient group.



Administration



The pre-filled syringe of PROSTAP SR microsphere powder should be reconstituted immediately prior to administration by subcutaneous or intramuscular injection.



To prepare for injection, screw the plunger rod into the end stopper until the end stopper begins to turn.



While holding the syringe upright, depress the plunger slowly by pushing the plunger rod until the middle stopper is at the blue line in the middle of the barrel.



NOTE: Pushing the plunger rod quickly or over the blue line will cause leakage of the suspension from the needle.



Gently tap the syringe on the palm keeping the syringe upright to thoroughly mix the particles to form a uniform suspension. The suspension will appear milky.



NOTE: Avoid hard tapping to prevent the generation of bubbles.



Remove the sheath and advance the plunger rod to expel the air from the syringe.



Inject the entire contents of the syringe subcutaneously or intramuscularly as you would for a normal injection.



4.3 Contraindications



Hypersensitivity to the active substance, any of the excipients or to synthetic gonadotrophin releasing homone (Gn-RH) or Gn-RH derivatives.



Women: PROSTAP SR is contra-indicated in women who are or may become pregnant while receiving the drug. PROSTAP SR should not be used in women who are breastfeeding or have undiagnosed abnormal vaginal bleeding.



Men: There are no known contra-indications to the use of PROSTAP SR in men.



4.4 Special Warnings And Precautions For Use



As would be expected with this class of drug, development or aggravation of diabetes may occur, therefore diabetic patients may require more frequent monitoring of blood glucose during treatment with PROSTAP SR.



Hepatic dysfunction and jaundice with elevated liver enzyme have been reported. Therefore, close observation should be made and appropriate measures taken if necessary.



Spinal fracture, paralysis, hypotension and worsening of depression have been reported.



Men: In the initial stages of therapy, a transient rise in levels of testosterone, dihydrotestosterone and acid phosphatase may occur. In some cases, this may be associated with a "flare" or exacerbation of the tumour growth resulting in temporary deterioration of the patient's condition. These symptoms usually subside on continuation of therapy. "Flare" may manifest itself as systemic or neurological symptoms in some cases.



In order to reduce the risk of “flare”, an anti-androgen may be administered beginning 3 days prior to leuprorelin acetate therapy and continuing for the first two to three weeks of treatment. This has been reported to prevent the sequelae of an initial rise in serum testosterone.



Patients at risk of ureteric obstruction or spinal cord compression should be considered carefully and closely supervised in the first few weeks of treatment. These patients should be considered for prophylactic treatment with anti-androgens. Should urological/neurological complications occur, these should be treated by appropriate specific measures.



If an anti-androgen is used over a prolonged period, due attention should be paid to the contra-indications and precautions associated with its extended use.



Whilst the development of pituitary adenomas has been noted in chronic toxicity studies at high doses in some animal species, this has not been observed in long term clinical studies with leuprorelin acetate.



Women: When considering the preoperative treatment of fibroids it is mandatory to confirm the diagnosis of fibroids and exclude an ovarian mass, either visually by laparoscopy or by ultrasonography or other investigative technique, as appropriate, before PROSTAP SR therapy is instituted.



During the early phase of therapy, sex steroids temporarily rise above baseline because of the physiological effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed during the initial days of therapy, but these will dissipate with continued therapy.



The induced hypo-estrogenic state results in a small loss in bone density over the course of treatment, some of which may not be reversible. The extent of bone demineralisation due to hypo-estrogenaemia is proportional to time and, consequently, is the adverse event responsible for limiting the duration of therapy to 6 months. The generally accepted level of bone loss with LHRH analogues such as PROSTAP SR is 5%. In clinical studies with PROSTAP SR the levels varied between 2.3% and 15.7% depending on the method of measurement. During one six-month treatment period, this bone loss should not be important. In patients with major risk factors for decreased bone mineral content such as chronic alcohol and/or tobacco use, strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids, PROSTAP SR therapy may pose an additional risk. In these patients, the risks and benefits must be weighed carefully before therapy with PROSTAP SR is instituted. This is particularly important in women with uterine fibroids where age related bone loss may have already begun to occur.



Therefore, before using PROSTAP SR for the preoperative treatment of uterine fibroids, patients with major risk factors for decreased bone mineral content (see above) should have their bone density measured and where results are below the normal (5th percentile by DEXA scan) range, PROSTAP SR therapy should not be started.



In women with submucous fibroids there have been reports of severe bleeding following the administration of PROSTAP SR as a consequence of the acute degeneration of the fibroids. Patients should be warned of the possibility of abnormal bleeding or pain in case earlier surgical intervention is required.



PROSTAP SR may cause an increase in uterine cervical resistance, which may result in difficulty in dilating the cervix for intrauterine surgical procedures.



In women receiving GnRH analogues for the treatment of endometriosis, the addition of HRT (an estrogen and progestogen) has been shown to reduce bone mineral density loss and vasomotor symptoms.



Precautions



Men: Patients with urinary obstruction and patients with metastatic vertebral lesions should begin PROSTAP SR therapy under close supervision for the first few weeks of treatment.



Women: Since menstruation should stop with effective doses of PROSTAP SR, the patient should notify her physician if regular menstruation persists.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No interaction studies have been performed.



4.6 Pregnancy And Lactation



Safe use of leuprorelin acetate in pregnancy has not been established clinically.



Studies in animals have shown reproductive toxicity (see section 5.3). Before starting treatment with PROSTAP SR, pregnancy must be excluded. There have been reports of foetal malformation when PROSTAP SR has been given during pregnancy.



PROSTAP SR should not be used in women who are breastfeeding.



When used monthly at the recommended dose, PROSTAP SR usually inhibits ovulation and stops menstruation. Contraception is not ensured, however, by taking PROSTAP SR and therefore patients should use non-hormonal methods of contraception during treatment.



Patients should be advised that if they miss successive doses of PROSTAP SR, breakthrough bleeding or ovulation may occur with the potential for conception. Patients should be advised to see their physician if they believe they may be pregnant. If a patient becomes pregnant during treatment, the drug must be discontinued. The patient must be apprised of this evidence and the potential for an unknown risk to the foetus.



4.7 Effects On Ability To Drive And Use Machines



PROSTAP SR can influence the ability to drive and use machines due to visual disturbances and dizziness.



4.8 Undesirable Effects



Side effects seen with PROSTAP SR are due mainly to the specific pharmacological action, namely increases and decreases in certain hormone levels. Adverse events which have been reported infrequently include peripheral oedema, pulmonary embolism, hypertension, palpitations, fatigue, muscle weakness, diarrhoea, nausea, vomiting, anorexia, fever/chills, headache (occasionally severe), hot flushes, arthralgia, myalgia, dizziness, insomnia, depression, paraesthesia, visual disturbances, weight changes, hepatic dysfunction, jaundice, increases in liver function test values (usually transient) and irritation at the injection site. Changes in blood lipids and alteration of glucose tolerance have also been reported which may affect diabetic control. Thrombocytopenia and leucopenia have been reported rarely. Hypersensitivity reactions including rash, pruritus, urticaria, and rarely, wheezing or interstitial pneumonitis have also been reported. Anaphylactic reactions are rare.



Spinal fracture, paralysis, hypotension and worsening of depression have been reported (see Section 4.4).



A reduction in bone mass may occur with the use of GnRH agonists.



Very rare cases of pituitary apoplexy have been reported following initial administration in patients with pituitary adenoma.



Men: In cases where a "tumour flare" occurs after PROSTAP SR therapy, an exacerbation may occur in any symptoms or signs due to disease, for example, bone pain, urinary obstruction, weakness of the lower extremities and paraesthesia. These symptoms subside on continuation of therapy.



Impotence and decreased libido will be expected with PROSTAP SR therapy.



The administration of PROSTAP SR is often associated with hot flushes and sometimes sweating.



Orchiatrophy and gynaecomastia have been reported occasionally.



Women: Those adverse events occurring most frequently with PROSTAP SR are associated with hypo-estrogenism; the most frequently reported are hot flushes, mood swings including depression (occasionally severe), and vaginal dryness. Estrogen levels return to normal after treatment is discontinued.



The induced hypo-estrogenic state results in a small loss in bone density over the course of treatment, some of which may not be reversible (see Section 4.4).



Breast tenderness or change in breast size may occur occasionally. Hair loss has also been reported occasionally.



Vaginal haemorrhage may occur during therapy due to acute degeneration of submucous fibroids (see Section 4.4).



4.9 Overdose



No case of overdose has been reported.



In animal studies, doses of up to 500 times the recommended human dose resulted in dyspnoea, decreased activity and local irritation at the injection site. In cases of overdose, the patients should be monitored closely and management should be symptomatic and supportive.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Gonadotrophin Releasing Hormone Analogues



ATC code: L02AE 02



PROSTAP SR contains leuprorelin acetate, a synthetic nonapeptide analogue of naturally occurring GnRH which possesses greater potency than the natural hormone. Leuprorelin acetate is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy.



Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Estradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.



The drug is well absorbed from the subcutaneous or intramuscular route, binds to luteinising hormone releasing hormone (LHRH) receptors and is rapidly degraded. In this dose form, an initial high level of leuprorelin acetate in the plasma is achieved within 3 hours followed by a drop over 24-48 hours to maintenance levels of 0.3-0.8ng/ml and a slow decline thereafter. Effective levels persist for 30-40 days after a single dose.



Leuprorelin acetate is inactive when given orally.



A randomised, open-label, comparative multi-centre study was performed to compare the efficacy and safety of the 3.75 mg and 11.25 mg depots of leuprorelin acetate. 48% of patients included had locally advanced disease (T3N0M0), 52% of patients had metastatic disease. Mean serum testosterone level fell below the threshold for chemical castration (0.5 ng/ml) at one month of treatment, continuing to decrease thereafter and stabilising at a value below the castration threshold. The decline in serum PSA mirrored that of serum testosterone in both groups.



In an open, prospective clinical trial involving 205 patients receiving 3.75 mg leuprorelin acetate on a monthly basis as treatment for metastatic prostate cancer, the long-term efficacy and safety of leuprorelin acetate was assessed. Testosterone levels were maintained below the castrate threshold over the 63-month follow up period. Median survival time exceeded 42.5 months for those receiving monotherapy and 30.9 months for those receiving leuprorelin acetate in combination with anti-androgens (this difference relating to baseline differences between groups)



In a meta-analysis involving primarily patients with metastatic disease, no statistically significant difference in survival was found for patients treated with LHRH analogues compared with patients treated with orchidectomy.



In another randomised, open-label, multi-centre comparative trial, leuprorelin acetate in combination with flutamide has been shown to significantly improve disease-free survival and overall survival when used as an adjuvant therapy to radiotherapy in 88 patients with high-risk localised (T1-T2 and PSA of at least 10 ng/mL or a Gleason score of at least 7), or locally advanced (T3-T4) prostate cancer. The optimum duration of adjuvant therapy has not been established. This US study used a higher dose of leuprorelin acetate (7.5mg/month) which is therapeutically equivalent to the European licensed dose.



The use of a LHRH agonist may be considered after prostatectomy in selected patients considered at high risk of disease progression. There are no disease-free survival data or survival data with leuprorelin acetate in this setting.



5.2 Pharmacokinetic Properties



Studies submitted show that single intramuscular or subcutaneous doses of leuprorelin acetate over the dose range 3.75 to 15 mg results in detectable levels of leuprorelin acetate for more than 28 days, good bioavailability, a consistent and predictable pharmacokinetic profile, and biological efficacy at plasma levels of less than 0.5 ng/ml. The pharmacokinetic profile is similar to that seen in animal studies using the compound, with an initial high level of drug released from the microcapsules during reconstitution and injection followed by a plateau over a 2-3 week period before levels gradually become undetectable. There appears to be no significant difference between the routes of administration (im vs sc) in biological effectiveness or pharmacokinetics.



The metabolism, distribution and excretion of leuprorelin acetate in humans have not been fully determined.



5.3 Preclinical Safety Data



A teratogenic effect has been observed in rabbits but not in rats.



6. Pharmaceutical Particulars



6.1 List Of Excipients



PROSTAP SR Powder



Gelatin



Copoly (DL lactic acid/glycolic acid) 72:25 mol%



Mannitol (E421)



Sterile Solvent



Carmellose sodium



Mannitol (E421)



Polysorbate 80



Glacial Acetic Acid (for pH adjustment)



Water for Injections



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



3 years unopened.



Once reconstituted with sterile solvent, the suspension should be administered immediately.



6.4 Special Precautions For Storage



Do not store above 25oC.



Do not refrigerate or freeze.



Store in the original container in order to protect from light.



6.5 Nature And Contents Of Container



One dual chamber pre-filled syringe containing 3.75 mg leuprorelin acetate powder in the front chamber and 1 ml of Sterile Solvent in the rear chamber.



1 x 25 gauge syringe needle



1 x syringe plunger



1 x injection site swab



6.6 Special Precautions For Disposal And Other Handling



Any unused product or waste material should be disposed of in accordance with local requirements.



7. Marketing Authorisation Holder



Takeda UK Limited



Takeda House



Mercury Park



Wooburn Green



High Wycombe



Bucks., HP10 0HH



UK



8. Marketing Authorisation Number(S)



16189/0012



9. Date Of First Authorisation/Renewal Of The Authorisation



28/04/2011



10. Date Of Revision Of The Text



28/04/2011




Tuesday, September 27, 2016

Prezista 75 mg, 150 mg, 400 mg, 600 mg film-coated tablets





1. Name Of The Medicinal Product



PREZISTA® 



PREZISTA® 



PREZISTA® 



PREZISTA® 


2. Qualitative And Quantitative Composition



75 mg film-coated tablet:



Each film-coated tablet contains 75 mg of darunavir (as ethanolate).



150 mg film-coated tablet:



Each film-coated tablet contains 150 mg of darunavir (as ethanolate).



400 mg film-coated tablet:



Each film-coated tablet contains 400 mg of darunavir (as ethanolate).



Excipient: Each tablet contains 0.834 mg sunset yellow FCF (E110).



600 mg film-coated tablet:



Each film-coated tablet contains 600 mg of darunavir (as ethanolate).



Excipient: Each tablet contains 2.750 mg sunset yellow FCF (E110).



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Film-coated tablet.



White caplet shaped tablet of 9.2 mm, debossed with “75” on one side and “TMC” on the other side.



White oval shaped tablet of 13.7 mm, debossed with “150” on one side and “TMC” on the other side.



Light orange oval shaped of 19.1 mm tablet, debossed with “400MG” on one side and “TMC” on the other side.



Orange oval shaped tablet of 21.1 mm, debossed with “600MG” on one side and “TMC” on the other side.



4. Clinical Particulars



4.1 Therapeutic Indications



PREZISTA, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.



PREZISTA 75 mg, 150 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):



• For the treatment of HIV-1 infection in antiretroviral treatment (ART) experienced adult patients, including those that have been highly pre-treated.



• For the treatment of HIV-1 infection in ART-experienced children and adolescents from the age of 6 years and at least 20 kg body weight.



In deciding to initiate treatment with PREZISTA co-administered with low dose ritonavir careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.



PREZISTA 400 mg tablets may be used to provide suitable dose regimens (see section 4.2):



• For the treatment of HIV-1 infection in antiretroviral therapy (ART) naïve adults.



• For the treatment of HIV-1 infection in ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count 6/l. In deciding to initiate treatment with PREZISTA in such ART-experienced adults genotypic testing should guide the use of PREZISTA (see sections 4.2, 4.3, 4.4 and 5.1).



4.2 Posology And Method Of Administration



Therapy should be initiated by a physician experienced in the management of HIV infection. After therapy with PREZISTA has been initiated, patients should be advised not to alter the dosage or discontinue therapy without instruction of their physician.



PREZISTA must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products. The Summary of Product Characteristics of ritonavir must therefore be consulted prior to initiation of therapy with PREZISTA.



Patients should be instructed to take PREZISTA with low dose ritonavir within 30 minutes after completion of a meal. The type of food does not affect the exposure to darunavir (see sections 4.4, 4.5 and 5.2).



Adults



ART-experienced patients



• For ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count 6/l, a dose regimen of 800 mg once daily with ritonavir 100 mg once daily taken with food may be used.



• In all other ART-experienced adults or if HIV-1 genotype testing is not available, the recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food. PREZISTA 75 mg and 150 mg tablets can be used to construct the twice daily 600 mg regimen. The use of 75 mg or 150 mg tablets to achieve the recommended dose is appropriate when there is a possibility of hypersensitivity to specific colouring agents, or difficulty in swallowing the 300 mg or 600 mg tablets.



* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V



ART-naïve patients



The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.



Paediatric population



ART-experienced paediatric patients (6 to 17 years of age and weighing at least 20 kg)














Recommended dose for treatment-experienced paediatric patients (6 to 17 years of age) for PREZISTA tablets and ritonavir


 


Body weight (kg)




Dose







375 mg PREZISTA/50 mg ritonavir twice daily







450 mg PREZISTA/60 mg ritonavir twice daily







600 mg PREZISTA/100 mg ritonavir twice daily



The recommended dose of PREZISTA with low dose ritonavir is based on body weight and should not exceed the recommended adult dose (600/100 mg twice daily).



The use of only 75 mg and 150 mg tablets to achieve the recommended dose of PREZISTA could be appropriate when there is a possibility of hypersensitivity to specific colouring agents.



ART-experienced children less than 6 years of age or less than 20 kg body weight, and ART-naïve paediatric patients



There are insufficient data on the use of PREZISTA with low dose ritonavir in children less than 6 years of age or less than 20 kg body weight. Hence, PREZISTA is not recommended for use in this group (see sections 4.4 and 5.3).



Elderly



Limited information is available in this population and therefore PREZISTA should be used with caution in this age group (see sections 4.4 and 5.2).



Hepatic impairment



Darunavir is metabolised by the hepatic system. No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, PREZISTA should be used with caution in these patients. No pharmacokinetic data are available in patients with severe hepatic impairment. Severe hepatic impairment could result in an increase of darunavir exposure and a worsening of its safety profile. Therefore, PREZISTA must not be used in patients with severe hepatic impairment (Child-Pugh Class C) (see sections 4.3, 4.4 and 5.2).



Renal impairment



No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).



In case a dose of PREZISTA and/or ritonavir was missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of PREZISTA and ritonavir with food as soon as possible. If this was noticed later than 6 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule.



This guidance is based on the 15 hour half-life of darunavir in the presence of ritonavir and the recommended dosing interval of approximately 12 hours.



If an 800/100 mg once daily dose of PREZISTA/ritonavir is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of PREZISTA and ritonavir with food as soon as possible. If this is noticed later than 12 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule.



This guidance is based on the 15 hour half-life of darunavir in the presence of ritonavir and the recommended dosing interval of approximately 24 hours.



4.3 Contraindications



Hypersensitivity to the active substance or to any of the excipients.



Patients with severe (Child-Pugh Class C) hepatic impairment.



Combination of rifampicin with PREZISTA with concomitant low dose ritonavir is contraindicated (see section 4.5).



The combination product lopinavir/ritonavir should not be used with PREZISTA because co-administration causes large decreases in darunavir concentrations, which may in turn significantly decrease the darunavir therapeutic effect (see section 4.5).



Herbal preparations containing St John's wort (Hypericum perforatum) must not be used while taking PREZISTA due to the risk of decreased plasma concentrations and reduced clinical effects of darunavir (see section 4.5).



Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. These active substances include e.g. antiarrhythmics (amiodarone, bepridil, quinidine, systemic lidocaine), alfuzosin, antihistamines (astemizole, terfenadine), ergot derivatives (e.g. dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (cisapride), neuroleptics (pimozide, sertindole), sedatives/hypnotics [triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5)], sildenafil (when used for the treatment of pulmonary arterial hypertension) and HMG-CoA reductase inhibitors (simvastatin and lovastatin) (see section 4.5).



4.4 Special Warnings And Precautions For Use



Patients should be advised that current antiretroviral therapy does not cure HIV and has not been proven to prevent the transmission of HIV to others through blood or sexual contact. Appropriate precautions should continue to be employed.



Regular assessment of virological response is advised. In the setting of lack or loss of virological response, resistance testing should be performed.



PREZISTA should only be used in combination with low dose ritonavir as a pharmacokinetic enhancer (see section 5.2).



Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations and is not recommended.



Darunavir binds predominantly to α1-acid glycoprotein. This protein binding is concentration dependent indicative for saturation of binding. Therefore, protein displacement of medicinal products highly bound to α1-acid glycoprotein cannot be ruled out (see section 4.5).



ART-experienced patients – once daily dosing



PREZISTA/rtv 800/100 mg once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA



6/l (see section 4.2). The efficacy and safety of PREZISTA/rtv 800/100 mg once daily in combination with optimised background regimen (OBR) for the treatment of HIV-1 infection in ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) was evaluated in one trial with a duration of 48 weeks. Combinations with OBRs other than



Paediatric population



PREZISTA is not recommended for use in children below 6 years of age or less than 20 kg body weight (see sections 4.2 and 5.3).



Elderly



As limited information is available on the use of PREZISTA in patients aged 65 and over, caution should be exercised in the administration of PREZISTA in elderly patients, reflecting the greater frequency of decreased hepatic function and of concomitant disease or other therapy (see sections 4.2 and 5.2).



Severe skin reactions



During the clinical development program (N=3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients. Stevens-Johnson Syndrome has been rarely (< 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis has been reported. Discontinue PREZISTA/rtv immediately if signs or symptoms of severe skin reactions develop. These can include but are not limited to severe rash or rash accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.



Rash occurred more commonly in treatment-experienced patients receiving regimens containing PREZISTA + raltegravir compared to patients receiving PREZISTA without raltegravir or raltegravir without PREZISTA (see section 4.8).



Darunavir contains a sulphonamide moiety. PREZISTA should be used with caution in patients with a known sulphonamide allergy.



Hepatotoxicity



Drug-induced hepatitis (e.g. acute hepatitis, cytolytic hepatitis) has been reported with PREZISTA/rtv. During the clinical development program (N=3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with PREZISTA/rtv. Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.



Appropriate laboratory testing should be conducted prior to initiating therapy with PREZISTA/rtv and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases, especially during the first several months of PREZISTA/rtv treatment.



If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using PREZISTA/rtv, interruption or discontinuation of treatment should be considered promptly.



Patients with coexisting conditions



Hepatic impairment



The safety and efficacy of PREZISTA have not been established in patients with severe underlying liver disorders and PREZISTA is therefore contraindicated in patients with severe hepatic impairment. Due to an increase in the unbound darunavir plasma concentrations, PREZISTA should be used with caution in patients with mild or moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).



Renal impairment



No special precautions or dose adjustments are required in patients with renal impairment. As darunavir and ritonavir are highly bound to plasma proteins, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis. Therefore, no special precautions or dose adjustments are required in these patients (see sections 4.2 and 5.2).



Haemophiliac patients



There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with PIs. In some patients additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced if treatment had been discontinued. A causal relationship has been suggested, although the mechanism of action has not been elucidated. Haemophiliac patients should therefore be made aware of the possibility of increased bleeding.



Diabetes mellitus/Hyperglycaemia



New onset diabetes mellitus, hyperglycaemia, or exacerbation of existing diabetes mellitus has been reported in patients receiving antiretroviral therapy, including PIs. In some of these patients the hyperglycaemia was severe and in some cases also associated with ketoacidosis. Many patients had confounding medical conditions some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycaemia.



Fat redistribution and metabolic disorders



Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV infected patients. The long-term consequences of these events are currently unknown. Knowledge about the mechanism is incomplete. A connection between visceral lipomatosis and PIs and lipoatrophy and NRTIs has been hypothesised. A higher risk of lipodystrophy has been associated with individual factors such as older age and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution. Consideration should be given to measurement of fasting serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate (see section 4.8).



Osteonecrosis



Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.



Immune reactivation syndrome



In HIV infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii). Any inflammatory symptoms should be evaluated and treatment instituted when necessary. In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical studies with PREZISTA co-administered with low dose ritonavir.



Interactions with medicinal products



Several of the interaction studies have been performed at lower than recommended doses of darunavir. The effects on co-administered medicinal products may thus be underestimated and clinical monitoring of safety may be indicated. For full information on interactions with other medicinal products see section 4.5.



Efavirenz in combination with PREZISTA/rtv 800/100 mg once daily may result in sub-optimal darunavir Cmin. If efavirenz is to be used in combination with PREZISTA/rtv, the PREZISTA/rtv 600/100 mg twice daily regimen should be used (see section 4.5).



Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A and Pgp (see section 4.5).



PREZISTA 400 mg and 600 mg tablets contain sunset yellow FCF (E110) which may cause an allergic reaction.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Darunavir and ritonavir are both inhibitors of the CYP3A isoform. Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP3A may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.



PREZISTA co-administered with low dose ritonavir must not be combined with medicinal products that are highly dependent on CYP3A for clearance and for which increased systemic exposure is associated with serious and/or life-threatening events (narrow therapeutic index). These medicinal products include amiodarone, bepridil, quinidine, systemic lidocaine, astemizole, alfuzosin, terfenadine, sildenafil (when used for the treatment of pulmonary arterial hypertension), midazolam administered orally, triazolam, cisapride, pimozide, sertindole, simvastatin, lovastatin and the ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine and methylergonovine) (see section 4.3).



The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily. Therefore, PREZISTA must only be used in combination with low dose ritonavir as a pharmacokinetic enhancer (see sections 4.4 and 5.2).



A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of PREZISTA/rtv, which may be attributed to the presence of low dose ritonavir. Co-administration of darunavir and ritonavir and medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.



Although the effect on CYP2C8 has only been studied in vitro, co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP2C8 (such as paclitaxel, rosiglitazone, repaglinide) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.



Medicinal products that affect darunavir/ritonavir exposure



Darunavir and ritonavir are metabolised by CYP3A. Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir (e.g. rifampicin, St John's wort, lopinavir). Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, systemic azoles like ketoconazole and clotrimazole). These interactions are described in the interaction table below.



Interaction table



Interactions between darunavir/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below (not determined as “ND”. The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (



Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). The effects on co-administered medicinal products may thus be underestimated and clinical monitoring of safety may be indicated.

















































































































INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS


  


Medicinal products by therapeutic areas




Interaction



Geometric mean change (%)




Recommendations concerning co-administration




ANTIRETROVIRALS


  


Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)


  


Didanosine



400 mg once daily




didanosine AUC



didanosine Cmin ND



didanosine Cmax



darunavir AUC ↔



darunavir Cmin ↔



darunavir Cmax ↔




PREZISTA co-administered with low dose ritonavir and didanosine can be used without dose adjustments.



Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after PREZISTA/ritonavir given with food.




Tenofovir



300 mg once daily




tenofovir AUC ↑ 22%



tenofovir Cmin ↑ 37%



tenofovir Cmax ↑ 24%



#darunavir AUC ↑ 21%



#darunavir Cmin ↑ 24%



#darunavir Cmax ↑ 16%(↑ tenofovir from effect on MDR-1 transport in the renal tubules)




Monitoring of renal function may be indicated when PREZISTA co-administered with low dose ritonavir is given in combination with tenofovir, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.




Abacavir



Emtricitabine



Lamivudine



Stavudine



Zidovudine




Not studied. Based on the different elimination pathways of the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are primarily renally excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and PREZISTA co-administered with low dose ritonavir.




PREZISTA co-administered with low dose ritonavir can be used with these NRTIs without dose adjustment.




Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)


  


Efavirenz



600 mg once daily




efavirenz AUC ↑ 21%



efavirenz Cmin ↑ 17%



efavirenz Cmax ↑ 15%



#darunavir AUC



#darunavir Cmin



#darunavir Cmax



(↑ efavirenz from CYP3A inhibition)



(




Clinical monitoring for central nervous system toxicity associated with increased exposure to efavirenz may be indicated when PREZISTA co-administered with low dose ritonavir is given in combination with efavirenz.



Efavirenz in combination with PREZISTA/rtv 800/100 mg once daily may result in sub-optimal darunavir Cmin. If efavirenz is to be used in combination with PREZISTA/rtv, the PREZISTA/rtv 600/100 mg twice daily regimen should be used (see section 4.4).




Etravirine



100 mg twice daily




etravirine AUC



etravirine Cmin



etravirine Cmax



darunavir AUC ↑ 15%



darunavir Cmin ↔



darunavir Cmax ↔




PREZISTA co-administered with low dose ritonavir and etravirine 200 mg twice daily can be used without dose adjustments.




Nevirapine



200 mg twice daily




nevirapine AUC ↑ 27%



nevirapine Cmin ↑ 47%



nevirapine Cmax ↑ 18%



#darunavir: concentrations were consistent with historical data



(↑ nevirapine from CYP3A inhibition)




PREZISTA co-administered with low dose ritonavir and nevirapine can be used without dose adjustments.




Protease inhibitors (PIs) - without additional co-administration of low dose ritonavir†


  


Atazanavir



300 mg once daily




atazanavir AUC ↔



atazanavir Cmin ↑ 52%



atazanavir Cmax



#darunavir AUC ↔



#darunavir Cmin ↔



#darunavir Cmax ↔



Atazanavir: comparison of atazanavir/ritonavir 300/100 mg once daily vs. atazanavir 300 mg once daily in combination with darunavir/ritonavir 400/100 mg twice daily.



Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg twice daily in combination with atazanavir 300 mg once daily.




PREZISTA co-administered with low dose ritonavir and atazanavir can be used without dose adjustments.




Indinavir



800 mg twice daily




indinavir AUC ↑ 23%



indinavir Cmin ↑ 125%



indinavir Cmax ↔



#darunavir AUC ↑ 24%



#darunavir Cmin ↑ 44%



#darunavir Cmax ↑ 11%



Indinavir: comparison of indinavir/ritonavir 800/100 mg twice daily vs. indinavir/darunavir/ritonavir 800/400/100 mg twice daily.



Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with indinavir 800 mg twice daily.




When used in combination with PREZISTA co-administered with low dose ritonavir, dose adjustment of indinavir from 800 mg twice daily to 600 mg twice daily may be warranted in case of intolerance.




Saquinavir



1,000 mg twice daily




#darunavir AUC



#darunavir Cmin



#darunavir Cmax



saquinavir AUC



saquinavir Cmin



saquinavir Cmax



Saquinavir: comparison of saquinavir/ritonavir 1,000/100 mg twice daily vs. saquinavir/darunavir/ritonavir 1,000/400/100 mg twice daily



Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily




It is not recommended to combine PREZISTA co-administered with low dose ritonavir with saquinavir.




Protease inhibitors (PIs) - with co-administration of low dose ritonavir†


  


Lopinavir/ritonavir



400/100 mg twice daily



 



 



 



 



 



Lopinavir/ritonavir



533/133.3 mg twice daily




lopinavir AUC ↑ 9%



lopinavir Cmin ↑ 23%



lopinavir Cmax



darunavir AUC ‡



darunavir Cmin‡



darunavir Cmax‡



lopinavir AUC ↔



lopinavir Cmin ↑ 13%



lopinavir Cmax ↑ 11%



darunavir AUC



darunavir Cmin



darunavir Cmax



‡ based upon non dose normalised values




Due to a decrease in the exposure (AUC) of darunavir by 40%, appropriate doses of the combination have not been established. Hence, concomitant use of PREZISTA co-administered with low dose ritonavir and the combination product lopinavir/ritonavir is contraindicated (see section 4.3).




CCR5 ANTAGONIST


  


Maraviroc



150 mg twice daily




maraviroc AUC ↑ 305%



maraviroc Cmin ND



maraviroc Cmax ↑ 129%



darunavir, ritonavir concentrations were consistent with historical data




The maraviroc dose should be 150 mg twice daily when co-administered with PREZISTA with low dose ritonavir.




ANTIARRHYTHMIC


  


Digoxin



0.4 mg single dose




digoxin AUC ↑ 61%



digoxin Cmin ND



digoxin Cmax ↑ 29%



(↑ digoxin from probable inhibition of Pgp)




Given that digoxin has a narrow therapeutic index, it is recommended that the lowest possible dose of digoxin should initially be prescribed in case digoxin is given to patients on darunavir/ritonavir therapy. The digoxin dose should be carefully titrated to obtain the desired clinical effect while assessing the overall clinical state of the subject.




ANTIBIOTIC


  


Clarithromycin



500 mg twice daily




clarithromycin AUC ↑ 57%



clarithromycin Cmin ↑ 174%



clarithromycin Cmax ↑ 26%



#darunavir AUC



#darunavir Cmin ↑ 1%



#darunavir Cmax



14-OH-clarithromycin concentrations were not detectable when combined with PREZISTA/ritonavir.



(↑ clarithromycin from CYP3A inhibition and possible Pgp inhibition)




Caution should be exercised when clarithromycin is combined with PREZISTA co-administered with low dose ritonavir.




ANTICOAGULANT


  


Warfarin




Not studied. Warfarin concentrations may be affected when co-administered with darunavir with low dose ritonavir.




It is recommended that the international normalised ratio (INR) be monitored when warfarin is combined with PREZISTA co-administered with low dose ritonavir.




ANTICONVULSANTS


  


Phenobarbital



Phenytoin




Not studied. Phenobarbital and phenytoin are expected to decrease plasma concentrations of darunavir.



(induction of CYP450 enzymes)




PREZISTA co-administered with low dose ritonavir should not be used in combination with these medicines.




Carbamazepine



200 mg twice daily




carbamazepine AUC ↑ 45%



carbamazepine Cmin ↑ 54%



carbamazepine Cmax ↑ 43%



darunavir AUC ↔



darunavir Cmin



darunavir Cmax ↔




No dose adjustment for PREZISTA/ritonavir is recommended. If there is a need to combine PREZISTA/ritonavir and carbamazepine, patients should be monitored for potential carbamazepine-related adverse events. Carbamazepine concentrations should be monitored and its dose should be titrated for adequate response. Based upon the findings, the carbamazepine dose may need to be reduced by 25% to 50% in the presence of PREZISTA/ritonavir.




ANTIFUNGALS


  


Voriconazole




Not studied. Ritonavir may decrease plasma concentrations of voriconazole.



(induction of CYP450 enzymes by ritonavir)




Voriconazole should not be combined with PREZISTA co-administered with low dose ritonavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole.




Ketoconazole



200 mg twice daily




ketoconazole AUC ↑ 212%



ketoconazole Cmin ↑ 868%



ketoconazole Cmax ↑ 111%



#darunavir AUC ↑ 42%



#darunavir Cmin ↑ 73%



#darunavir Cmax ↑ 21%



(CYP3A inhibition)




Caution is warranted and clinical monitoring is recommended. When co-administration is required the daily dose of ketoconazole should not exceed 200 mg.




Itraconazole




Not studied. Concomitant systemic use of itraconazole and darunavir co-administered with low dose ritonavir may increase plasma concentrations of darunavir. Simultaneously, plasma concentrations of itraconazole may be increased by darunavir co-administered with low dose ritonavir.



(CYP3A inhibition)




Caution is warranted and clinical monitoring is recommended. When co-administration is required the daily dose of itraconazole should not exceed 200 mg.




Clotrimazole




Not studied. Concomitant systemic use of clotrimazole and darunavir co-administered with low dose ritonavir may increase plasma concentrations of darunavir.



darunavir AUC24h ↑ 33% (based on population pharmacokinetic model)




Caution is warranted and clinical monitoring is recommended, when co-administration of clotrimazole is required.




ANTIGOUT MEDICINES



 

 


Colchicine




Not studied. Concomitant use of colchicine and darunavir co-administered with low dose ritonavir may increase the exposure to colchicine.




A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with PREZISTA co-administered with low dose ritonavir is required. Patients with renal or hepatic impairment should not be given colchicine with PREZISTA co-administered with low dose ritonavir (see section 4.4).




ANTIMYCOBACTERIALS


  


Rifampicin




Not studied. Rifampicin is a strong CYP3A inducer and has been shown to cause profound decreases in concentrations of other p

Prostin E2 Sterile Solution 10 mg / ml Extra-Amniotic





Prostin E2 Sterile Solution 10 mg/ml



Dinoprostone



Pharmacia Logo




Read all of this leaflet carefully before you are given this medicine.



Keep this leaflet. You may need to read it again.



If you have any further questions, ask your doctor or nurse.



If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.





In this leaflet:



  • 1. What Prostin E2 Sterile Solution is and what it is used for


  • 2. Before you are given Prostin E2 Sterile Solution


  • 3. How Prostin E2 Sterile Solution is given to you


  • 4. Possible side effects


  • 5. How to store Prostin E2 Sterile Solution


  • 6. Further information





What Prostin E2 Sterile Solution is and what it is used for



Prostin E2 Sterile Solution contains the prostaglandin dinoprostone and is used to “induce” labour. This means that the medicine will help your uterus (womb) to start contracting and you will go into labour which will end the pregnancy. This is also called termination of pregnancy or an abortion. Dinoprostone is similar to the natural ‘E2’, type of prostaglandins which are made in your body when labour starts. It will only be given to you in a hospital or clinic. It is given to you as an infusion, directly into the womb.





Before you are given Prostin E2 Sterile Solution



Most women can be treated with Prostin E2. Some women may need extra checks during treatment and for some women a different treatment may be better. Your doctor or nurse will ask you questions before giving you Prostin E2 to make sure it is safe for you. If you do not understand any of the questions, ask your doctor or nurse to explain.



If you are having a pregnancy termination (abortion), it is very important for it to be complete. This is because prostaglandins given at this stage in pregnancy may cause abnormalities in the foetus. If your doctor thinks that the abortion has not worked completely, you will need another treatment, probably an operation.




Do not use Prostin E2 Sterile Solution:



  • If you have had an allergic reaction (e.g. wheezing, breathlessness, swelling of the hands, face, itchy rash or redness of the skin) to dinoprostone or any other prostaglandin or any of the other ingredients in the infusion, which are listed in Section 6 below.


  • If you have current heart, lung, kidney or liver disease

Your doctor or nurse will not use Prostin E2 to start or strengthen your labour in certain circumstances if:



  • you have had a Caesarean section or any major surgery to your womb in the past


  • you had any abnormal contractions of your womb that were too strong or went on for too long during a previous labour


  • you have an infection of your womb, ovaries or tubes (pelvic inflammatory disease) unless you are receiving treatment for these, or if you have ever had such an infection in the past


  • you have been told that you will have an obstructed labour




Take special care with Prostin E2 Sterile Solution:



Tell your doctor or nurse if you have or have had in the past any of the following conditions as they may want to monitor you more closely.



  • heart, lung, kidney or liver disease


  • glaucoma (raised pressure in the eye)


  • epilepsy


  • suffered from asthma


  • hypertension (high blood pressure) at any time, including during this or any previous pregnancy


  • been told you had abnormally strong contractions of your womb during a previous labour


  • scarring of your womb from a previous operation

Your doctor or nurse will ask you questions before giving you Prostin E2 to make sure it is safe for you.



If you do not understand any of the questions, ask your doctor or nurse to explain.





Taking other medicines:



Prostin E2 Sterile Solution can make you more sensitive to another medicine called oxytocin which is used to strengthen contractions. Medical staff will normally try not to use this medicine at the same time as Prostin E2 Sterile Solution. If used with this medicine in sequence, your doctor or nurse will watch over the womb contractions very carefully.



Your doctor may give you antibiotics before you start this prostaglandin treatment.



Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.





Pregnancy and breastfeeding



Prostin E2 will only be given to you in the late stages of pregnancy to induce labour.



Although prostaglandins are present in breast milk, you are not expected to be breast-feeding as this medicine is used to terminate the pregnancy.





Driving and using machinery



No effect on your ability to drive or use machinery is expected after being given Prostin E2.






How Prostin E2 Sterile Solution is given to you



This product can only be used in hospitals and clinics with specialised units for pregnancy and childbirth (obstetric units). Medical staff will be available at all times.



Prostin E2 Sterile Solution is diluted before use with the 50 ml of diluent supplied, to make a solution containing 100 micrograms/ml. The 100 micrograms/ml solution is instilled (placed drop by drop) into the womb, using a fine tube that is passed up into the womb through your vagina and cervix (neck of the womb). Medical staff will adjust the dose to suit you. At first 1 ml of solution is given. Then depending on how your womb responds, another 1 ml or 2 ml may be given at two-hourly intervals. The doctor or nurse will want to make sure that the contractions do not become too strong.



Medical staff will be keeping a very close eye on you during your treatment. They should be able to act quickly if you have side-effects or if your womb reacts too strongly to the dose you are given. You might just need a lower dose, or you might need some other obstetric procedure.



You should not normally be given Prostin E2 Sterile Solution for more than two days at a time.



Your doctor or nurse will do internal checks to make sure that your cervix is opening enough. They will also check your contractions to make sure that they are not too strong.




If you are given too much Prostin E2 Sterile Solution



Tell your doctor or nurse if you think you have been given too much Prostin E2 Sterile Solution. Symptoms of this would be excessive contractions of your womb (very strong, frequent and painful contractions) or severe side-effects, such as feeling and being sick. If you have such symptoms, the rate at which Prostin E2 Sterile Solution is being given should be reduced, or the treatment should be stopped. If you have a massive overdose, so that the muscles of your womb become very tense and over-active, you might need another obstetric procedure.






Possible side effects



Like all medicines Prostin E2 Sterile Solution can cause side effects, although not everybody gets them.



If you have asthma, Prostin E2 Sterile Solution could cause you to have an asthmatic attack. You must tell your doctor or nurse if you suffer from asthma or if you start having difficulty in breathing.




Rare side effects



Rare but serious side effects which can sometimes happen include the following:



  • tearing or bursting of the wall of your womb (uterine rupture)


  • heart attack


  • allergic reactions (symptoms may include wheezing, breathlessness, swelling of the hands, face, itchy rash or redness of the skin). If you get any of these symptoms please tell your doctor or midwife straight away.




Common side effects



  • vomiting (being sick),


  • nausea (feeling sick)


  • diarrhoea

These have seldom been bad enough for the woman to stop the treatment.





Other side effects



As prostaglandins make the body go into labour in the same way as it would happen naturally, anything that can happen in a natural labour can also happen if you have been given Prostin E2. Talk to your nurse or doctor about this if you want to know more, as they will be able to give you the information that you need.



These include:



  • sudden blockage of a blood vessel with amniotic fluid (the fluid which surrounds the baby) or by a blood clot in the lungs. This could cause chest pain and shortness of breath.


  • abnormally strong, frequent or long contractions of the womb, slowing or quickening of the baby’s heart rate and distress in the baby


  • abnormally strong, frequent or long contractions of the womb, slowing or quickening of the baby’s heart rate and distress in the baby


  • high blood pressure in the mother


  • very quick opening of the cervix


  • running a high temperature


  • backache


  • rash


  • heart attack

In some women the number of white blood cells rises during treatment. This will not cause you any symptoms, but your doctor or nurse may mention this if you have a blood sample taken.



If you are still running a temperature after the Prostin E2 Sterile Solution has been stopped, the doctor or nurse will want to make sure that this is not caused by an infection. You may be given antibiotics to treat any infection.



If you have very long and strong contractions, the wall of the uterus could tear. (This can happen in natural labour too). This is one reason for close monitoring during treatment.



There may be a link between Prostin E2 Sterile Solution and cardiac arrest (stopping of the heart) in women who were already severely ill and who were given Prostin E2 Sterile Solution by injection into the muscle of the womb. This method of injections is not recommended.



If you think you may be having any of the above side effects, or you are worried about anything unusual happening during your labour, please tell your doctor or nurse.






How to store Prostin E2 Sterile Solution



The medicine will be kept out of the reach and sight of children.



Prostin E2 Sterile Solution will not be given to you after the expiry date which is stated on the packs. The expiry date refers to the last day of that month.



Your hospital pharmacist will store this medicine in a refrigerator at 4 °C before use.





Further information




What Prostin E2 Sterile Solution contain:



The active substance is called dinoprostone. It also contains ethanol (alcohol).



The liquid (diluent) supplied separately to dilute the Prostin E2 Sterile Solution stops the growth of bacteria, and contains sodium chloride (salt), benzyl alcohol and water.





What Prostin E2 Sterile Solution looks like and contents of the pack



Each pack contains:



  • one 0.5 ml ampoule (small, closed glass container) of Prostin E2 Sterile Solution;


  • one 50 ml vial (small glass bottle) of diluent.




Marketing Authorisation Holder:




Pharmacia Limited

Ramsgate Road

Sandwich

Kent

CT13 9NJ

UK





Manufacturer:




Pfizer Manufacturing Belgium NV

Rijksweg 12

B-2870 Puurs

Belgium




For further information on this medicine, please contact Pfizer Medical Information on: 01304 616161.




This leaflet was last updated in July 2008.



Ref: PR 1_1